These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19383903)

  • 1. Transcription inhibition of heat shock proteins: a strategy for combination of 17-allylamino-17-demethoxygeldanamycin and actinomycin d.
    Cervantes-Gomez F; Nimmanapalli R; Gandhi V
    Cancer Res; 2009 May; 69(9):3947-54. PubMed ID: 19383903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells.
    Cervantes-Gomez F; Nimmanapalli R; Gandhi V
    J Pharmacol Exp Ther; 2011 Nov; 339(2):545-54. PubMed ID: 21821695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.
    McCollum AK; TenEyck CJ; Stensgard B; Morlan BW; Ballman KV; Jenkins RB; Toft DO; Erlichman C
    Cancer Res; 2008 Sep; 68(18):7419-27. PubMed ID: 18794130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism.
    McCollum AK; Teneyck CJ; Sauer BM; Toft DO; Erlichman C
    Cancer Res; 2006 Nov; 66(22):10967-75. PubMed ID: 17108135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
    Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.
    Banerji U; Sain N; Sharp SY; Valenti M; Asad Y; Ruddle R; Raynaud F; Walton M; Eccles SA; Judson I; Jackman AL; Workman P
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):769-78. PubMed ID: 18193424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancer.
    Ma L; Sato F; Sato R; Matsubara T; Hirai K; Yamasaki M; Shin T; Shimada T; Nomura T; Mori K; Sumino Y; Mimata H
    Oncol Rep; 2014 Jun; 31(6):2482-92. PubMed ID: 24718854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.
    Sato A; Asano T; Ito K; Asano T
    Int J Oncol; 2012 Jul; 41(1):46-52. PubMed ID: 22470109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin abrogates the geldanamycin-induced heat shock response.
    McCollum AK; Lukasiewicz KB; Teneyck CJ; Lingle WL; Toft DO; Erlichman C
    Mol Cancer Ther; 2008 Oct; 7(10):3256-64. PubMed ID: 18852129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
    Guo F; Rocha K; Bali P; Pranpat M; Fiskus W; Boyapalle S; Kumaraswamy S; Balasis M; Greedy B; Armitage ES; Lawrence N; Bhalla K
    Cancer Res; 2005 Nov; 65(22):10536-44. PubMed ID: 16288046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
    Yasui H; Hideshima T; Ikeda H; Jin J; Ocio EM; Kiziltepe T; Okawa Y; Vallet S; Podar K; Ishitsuka K; Richardson PG; Pargellis C; Moss N; Raje N; Anderson KC
    Br J Haematol; 2007 Feb; 136(3):414-23. PubMed ID: 17173546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
    Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
    J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
    Rahmani M; Yu C; Dai Y; Reese E; Ahmed W; Dent P; Grant S
    Cancer Res; 2003 Dec; 63(23):8420-7. PubMed ID: 14679005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
    Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
    Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The small-molecule kinase inhibitor D11 counteracts 17-AAG-mediated up-regulation of HSP70 in brain cancer cells.
    Schaefer S; Svenstrup TH; Guerra B
    PLoS One; 2017; 12(5):e0177706. PubMed ID: 28542269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular stress-inducing compounds increase osteoclast formation in a heat shock factor 1 protein-dependent manner.
    Chai RC; Kouspou MM; Lang BJ; Nguyen CH; van der Kraan AG; Vieusseux JL; Lim RC; Gillespie MT; Benjamin IJ; Quinn JM; Price JT
    J Biol Chem; 2014 May; 289(19):13602-14. PubMed ID: 24692538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma.
    Duus J; Bahar HI; Venkataraman G; Ozpuyan F; Izban KF; Al-Masri H; Maududi T; Toor A; Alkan S
    Leuk Lymphoma; 2006 Jul; 47(7):1369-78. PubMed ID: 16923571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
    George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K
    Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17-AAG improves cognitive process and increases heat shock protein response in a model lesion with Aβ25-35.
    Ortega L; Calvillo M; Luna F; Pérez-Severiano F; Rubio-Osornio M; Guevara J; Limón ID
    Neuropeptides; 2014 Aug; 48(4):221-32. PubMed ID: 24819277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of multiple heat shock proteins and neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis.
    Batulan Z; Taylor DM; Aarons RJ; Minotti S; Doroudchi MM; Nalbantoglu J; Durham HD
    Neurobiol Dis; 2006 Nov; 24(2):213-25. PubMed ID: 16950627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.